First-Line T-DXd Combinations Show Early Antitumor Activity in HER2+ Gastric/GEJ Cancers
T-DXd, with or without pembrolizumab and fluoropyrimidine, showed antitumor activity and manageable safety in HER2-positive esophageal, gastric, and GEJ cancer patients. Full-dose T-DXd and fluoropyrimidine had the highest ORR (78%), while pembrolizumab-containing arms showed higher toxicities. Reduced-dose triplets demonstrated manageable safety.
Related Clinical Trials
Reference News
T-DXd, with or without pembrolizumab and fluoropyrimidine, showed antitumor activity and manageable safety in HER2-positive esophageal, gastric, and GEJ cancer patients. Full-dose T-DXd and fluoropyrimidine had the highest ORR (78%), while pembrolizumab-containing arms showed higher toxicities. Reduced-dose triplets demonstrated manageable safety.
Trastuzumab deruxtecan (T-DXd) combined with fluoropyrimidine (FP) and/or pembrolizumab showed significant antitumor activity in HER2+ esophageal, gastric, and gastroesophageal junction cancer, according to the DESTINY-Gastric03 study. Full-dose T-DXd and FP achieved the highest overall response rate (78%), while the triplet of T-DXd, FP, and pembrolizumab showed higher toxicities. A reduced-dose triplet demonstrated manageable safety. Further research is needed.